Onyx Pharmaceuticals Inc. and partner Bayer Healthcare Pharmaceuticals Inc. reported detailed results from their positive Phase III trial of Nexavar (sorafenib) in liver cancer, which has emerged as one of the biggest headlines at this year's American Society of Clinical Oncology meeting in Chicago. (BioWorld Today) Read More
